Blog Detail

McKesson Builds $179M Automated Pharma Distribution Hub with Cold Chain Capability

Source: The Journal Record; supporting source: Modern Distribution Management

McKesson’s Moore Distribution Hub Shows How Pharma Cold Chain Is Moving Toward Automated Regional Control

What Happened

McKesson is building a new $179 million regional pharmaceutical distribution hub in Moore, Oklahoma. The 330,000-square-foot facility will be located in the North Moore Industrial Park and is expected to replace an older regional center in Oklahoma City.

The project is designed to consolidate Midwest distribution operations and strengthen McKesson’s ability to serve Oklahoma, Texas and nearby markets. According to local reporting, the new hub will use automation, robotics and cold-chain technology, and is expected to support more than 600 jobs by 2029.

The facility is being positioned as a more resilient healthcare supply chain node rather than a conventional warehouse. McKesson’s U.S. Pharmaceutical Distribution leadership described the project as a long-term efficiency move, with the site selected for infrastructure, workforce and regional access.

How It Works

A pharmaceutical distribution center is not simply a storage building. It is a controlled operating environment where inventory accuracy, temperature control, order prioritization, regulatory documentation and outbound logistics all affect patient access.

The Moore facility will replace an older regional center and add modernized capabilities for high-volume pharmaceutical distribution. Reporting on the project identifies precise climate control, predictive data, robotics and next-generation cold chain capability as part of the design.

Modern Distribution Management also reported that the facility will include digitally enabled logistics, automation, precision inventory management, expanded cold chain capacity and full standby power to support operations during adverse conditions.

For pharmaceutical distribution, those features matter because different products require different handling profiles. Some products can move under controlled room temperature conditions, while others require refrigerated storage, frozen handling or other specialized protection. A modern healthcare distribution node must therefore manage multiple storage zones, inventory rules and outbound routing priorities at the same time.

Automation and robotics can help reduce manual touches, improve pick accuracy and support faster order flow. AI and predictive data can help forecast demand, allocate inventory and manage routing more effectively. But in a pharma cold chain environment, the most important requirement is that automation must work inside a quality-controlled process.

That means every technology layer should support documented product integrity: correct SKU identification, correct storage condition, correct lot control, correct outbound destination and clear exception handling if a temperature or inventory deviation occurs.

Why It Matters

The project reflects a larger shift in U.S. pharmaceutical distribution. Healthcare supply chains are becoming more regionalized, automated and temperature-sensitive.

More medicines now require specialized handling, including biologics, specialty injectables, vaccines, GLP-1 products, oncology drugs and other therapies that may have stricter stability profiles than conventional small-molecule medicines. This increases demand for distribution centers that can combine high throughput with temperature discipline and audit-ready control.

The Moore site also highlights the importance of resilience. A healthcare distributor cannot treat power outages, weather disruptions or transportation delays as ordinary warehouse interruptions. If a facility is responsible for supplying hospitals, pharmacies and healthcare providers, operational continuity directly affects patient access.

Full standby power is especially important for cold-chain operations. Refrigerated and frozen products can be put at risk if a facility loses power without sufficient backup systems. Standby power does not replace quality systems, but it reduces the probability that a regional disruption becomes a temperature excursion or product-loss event.

The investment also shows how cold chain capability is becoming embedded into general pharmaceutical distribution networks rather than being treated as a niche service. As more therapies require controlled storage, cold chain operations must be integrated with standard distribution, inventory management and transportation planning.

B2B Impact

For pharmaceutical manufacturers, the McKesson project reinforces the need to evaluate distribution partners by regional cold chain readiness, not only national coverage.

A distributor may have broad market reach, but product integrity depends on the performance of each regional node. Manufacturers should assess whether a facility has validated storage zones, temperature mapping, alarm escalation, backup power, calibrated monitoring devices and clear deviation procedures.

For healthcare distributors, the project demonstrates the direction of competitive investment. Future-ready distribution centers will likely combine automation, robotics, AI-assisted planning and expanded cold chain capacity. Speed matters, but accuracy and documented control matter more in regulated healthcare supply.

For cold chain equipment suppliers, this type of facility creates demand for integrated refrigeration systems, temperature sensors, backup power interfaces, cold-room doors, insulated panels, monitoring software and warehouse layouts that support both temperature control and high-speed picking.

For data logger and visibility providers, the opportunity is to connect facility-level temperature records with order-level shipment data. A quality team should be able to see not only that a cold room remained within range, but also which products, lots and outbound orders were exposed to which conditions at each step.

For logistics providers, the Moore hub may increase demand for regional transportation lanes that can preserve product integrity from facility release to healthcare delivery. Refrigerated transport, controlled-room-temperature delivery, route monitoring and proof-of-delivery documentation will become more important as distribution centers handle more temperature-sensitive inventory.

The broader lesson is that pharmaceutical cold chain infrastructure is moving from isolated cold rooms toward integrated regional control systems. McKesson’s investment shows how automation, climate control, inventory precision and continuity planning are becoming part of the same healthcare logistics platform.